Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01744418|
Recruitment Status : Active, not recruiting
First Posted : December 6, 2012
Last Update Posted : March 5, 2021
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG.
The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
|Condition or disease||Intervention/treatment||Phase|
|End-stage Renal Disease Kidney Failure, Chronic||Device: HAVG graft implantation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|
|Actual Study Start Date :||December 2012|
|Actual Primary Completion Date :||April 2016|
|Estimated Study Completion Date :||April 2026|
Experimental: HAVG graft
HAVG graft implantation to study participants.
Device: HAVG graft implantation
Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
Other Name: Human Acellular Vascular Graft
- HAVG safety & tolerability [ Time Frame: At each visit within first 6 months after HAVG implantation. ]The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be tabulated by visit and overall.
- HAVG patency rate [ Time Frame: At 6 months after HAVG implantation. ]Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG.
- PRA response [ Time Frame: At screening, day 15, 29, 57 and week 12, 26 ]Assess changes in the PRA response over the 6 months after graft implantation.
- IgG antibodies [ Time Frame: At screening, day 15, 29, 57 and week 12, 26 ]Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG.
- Patency maintenance/restoration [ Time Frame: At each visit except screening. ]Determine the rates of interventions needed to maintain / restore patency in the graft.
- HAVG patency rates [ Time Frame: At 12, 18, 24 months after HAVG implantation. ]Patency rates (primary, primary assisted and secondary) at 12, 18 and 24 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01744418
|Department of Vascular Surgery and Angiology at the Medical University Lublin|
|Lublin, Poland, 20-081|
|Independent Public Central Clinical Hospital in Warsaw; Department of General, Vascular and Transplant Surgery|
|Warsaw, Poland, 02-097|
|Regional Specialist Hospital in Wroclaw; Clinic of Vascular Surgery|
|Wroclaw, Poland, 51-124|
|Study Director:||Kiernan DeAngelis, MD||Humacyte, Inc.|